surmount-osa trial tirzepatide results and Potential Role of in Treating Obesity-Related Obstructive Sleep Apnea — @atulmalhotra13 and @ljaronne presented Friday at #ADASciSessions. Read a recap in ADA Meeting News: https://t.co/Dg0qxKO7Pp SURPASS to SURMOUNT: The Tirzepatide
Description
The danger exists only when you confuse one for the other
It is also commonly associated with weight management support when paired with diet and lifestyle changes
The maximum approved dose is 15 mg once weekly
In the SURMOUNT trials, participants experienced significant reductions in fasting insulin, HbA1c (even in non-diabetic participants), triglycerides, and blood pressure
So frustrating
